<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782834</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107DUS05T</org_study_id>
    <nct_id>NCT00782834</nct_id>
  </id_info>
  <brief_title>Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)</brief_title>
  <acronym>07060</acronym>
  <official_title>Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of Nilotinib for patients with advanced GIST that cannot be
      surgically removed. Patients are candidates for the study if their tumors have progressed on
      imatinib and sunitinib or if they were intolerant to these drugs. Patients may have received
      other investigational therapies as well. We are testing the benefit of nilotinib in advanced
      GIST looking at the length of time disease is controlled as well as the response of the
      disease to the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nilotinib is an oral drug. The dose is 400 mg twice daily

      Patients are evaluated every 8 weeks for disease response. Blood work is assessed for safety
      initially weekly, then every 4 weeks. Physical exams are performed initially weekly and then
      decreased to every 4 weeks after the first month.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped early for futility, unable to meet accrual goals
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants that demonstrate progression free survival at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>1year</time_frame>
    <description>Response rate of nilotinib by RECIST criteria evaluated every 2 months for the first 6 months then every 3 months for the duration of treatment period.</description>
  </primary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>400 mg orally twice daily until disease progression, intolerability or withdrawal of consent</description>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients must have histologically or cytologically confirmed GIST

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             20 millimeters (mm) with conventional techniques or as &gt;= 10 mm with spiral CT scan.

          -  Patients may have received prior chemotherapy or radiation therapy. Patients must have
             recovered from any prior therapy and at least 4 weeks (6 weeks for nitrosoureas or
             mitomycin C; 2 weeks for limited field palliative radiation) must have elapsed since
             prior treatment.

          -  Patients must have received and progressed on imatinib and sunitinib. Except for
             nilotinib, patients may have received additional tyrosine kinase inhibitors or
             additional targeted therapies.

          -  Age &gt;= 18 years.

          -  Life expectancy of greater than 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count &gt;= 1,500/mcL

               -  platelets &gt;= 100,000/mcL

               -  total bilirubin &lt;= 1.5 times Upper Limits of Normal (ULN)

               -  AST(SGOT)/ALT(SGPT) &lt;= 2.5 X ULN OR &lt;= 5.0 X ULN if considered due to tumor

               -  Potassium, magnesium normal or corrected to normal limits prior to initiating
                  drug

               -  Calcium, phosphorus normal or corrected to normal limits prior to initiating drug

               -  creatinine within normal institutional limits

               -  creatinine clearance 24 hour creatinine clearance &gt;= 50 mL/min (calculation by
                  cockroft formula is acceptable)

          -  The effects of Nilotinib on the developing human fetus at the recommended therapeutic
             dose are unknown. Men or women of childbearing potential (WOCBP), to include female
             partners of heterosexual or bisexual patients, must agree to use an effective method
             of contraception during the study and for up to three months following termination of
             the study. Post menopausal women must be amenorrheic for at least 12 months to be
             considered of non-childbearing potential.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria

          -  Patients may not be receiving any other investigational agents within 4 weeks.

          -  Prior or concomitant malignancies (with a relapse in the last 5 years or requiring
             active treatment) other than GIST and with the exception of previous or concomitant
             basal cell skin cancer, previous cervical carcinoma in situ

          -  Impaired cardiac function at baseline, including any one of the following:

               -  Left Ventricular Ejection Fraction (LVEF)&lt; 45% or below the institutional Lower
                  Limits of Normal (LLN) range (whichever is higher)

               -  Complete left bundle branch block

               -  Use of a ventricular paced cardiac pacemaker

               -  Congenital long QT syndrome or family history of long QT syndrome

               -  History of or presence of significant ventricular or atrial tachyarrhythmias

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

               -  QTc &gt; 450 msec on screening ECG (using the QTcF formula). If QTc &gt; 450 msec and
                  electrolytes are not within normal ranges (electrolytes should be corrected and
                  then the patient rescreened for QTc.

               -  Right bundle branch block plus left anterior hemiblock, bifascicular block

               -  Myocardial infarction within 12 months prior to Visit 1

               -  Other clinically significant heart disease (e.g., unstable angina, congestive
                  heart failure or uncontrolled hypertension)

          -  Patients with severe and/or uncontrolled concurrent medical disease that in the
             opinion of the investigator could cause unacceptable safety risks or compromise
             compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI
             disease that may significantly alter the absorption of the study drugs, uncontrolled
             diabetes

          -  Use of therapeutic coumarin derivatives (i.e. warfarin, acenoucumarol, phenprocoumon)

          -  Use of any medications that prolong the QT interval and CYP3A4 inhibitors if the
             treatment cannot be either safely discontinued or switched to a different medication
             prior to starting study drug administration. Please see
             http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a
             comprehensive list of agents that prolong the QT interval as well as

          -  Patients who have undergone major surgery &lt;= 2 weeks prior to Visit 1 or who have not
             recovered from side effects of such surgery

          -  A history of noncompliance to medical regimens or inability or unwillingness to return
             for scheduled visits, patients who are pregnant or breast feeding, and patients
             unwilling or unable to comply with the requirements for the protocol.

          -  Patient has known chronic liver disease (i.e., chronic active hepatitis, and
             cirrhosis).

          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret von Mehren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.protonet.fccc.edu/cgi-bin/protocol/proto_detail.cgi?protocol_id=IRB07060&amp;hosp_id=24</url>
    <description>Protocol information on Fox Chase Cancer Center Clinical Trial Website</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>December 17, 2010</results_first_submitted>
  <results_first_submitted_qc>August 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2011</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>Nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were accrued between 7/03/2008 and 9/24/2009 at Fox Chase Cancer Center outpatient medical oncology clinics.</recruitment_details>
      <pre_assignment_details>Advanced GIST with measurable disease; previously treated with at least imatinib and sunitinib; a 5-day washout from prior tyrosine kinase inhibitor therapy. Normal cardiac function with LVEF 45% or &gt;, no history of significant heart disease,arrhythmias,congenital long QT sydrome, heart block, MI within 12 mos of visit 1 or unstable angina, CHF</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib Arm</title>
          <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screened Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">1 pt ineligible d/t arrhythmia</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>fibrous tumor not GIST</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Screened:
Started: 15 patients Completed: 14 patients Comments: 1 patient deemed ineligible due to arrhythmia.
Treatment Phase:
Started: 14 patients Completed: 13 patients Comments: 1 patient on extensive pathology review was found to have a solitary fibrous tumor, not GIST.</population>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib Arm</title>
          <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="54" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="68" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Site of Cancer</title>
          <description>Stomach 6; Small bowel 5; Colon 1; Rectum 1</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Bowel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Tyrosine Kinase Inhibitor (TKI)</title>
          <description>Imatinib (IM) + Sunitinib (SU); Imatinib + Sunitinib + Nasatinib (NA); Imatinib +Sunitinib + Radiotherapy (RT) + Chemotherapy (CT)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IM and SU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IM, SU and NA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IM, SU, RT and CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Rate at 6 Months</title>
        <description>Number of participants that demonstrate progression free survival at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib Arm</title>
            <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Rate at 6 Months</title>
          <description>Number of participants that demonstrate progression free survival at 6 months</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Response rate of nilotinib by RECIST criteria evaluated every 2 months for the first 6 months then every 3 months for the duration of treatment period.</description>
        <time_frame>1year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib Arm</title>
            <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response rate of nilotinib by RECIST criteria evaluated every 2 months for the first 6 months then every 3 months for the duration of treatment period.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib Arm</title>
          <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain associated with constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea vomiting weakness followed by death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Severe abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Profound weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status dec pulse ox</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute azotemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GI Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hoarseness voice changes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alk Phos</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SGOT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study failed to meet its accrual goals. Study terminated prior to accruing 17 subjects due to futility of meeting endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret von Mehren, M.D., Director of Sarcoma Oncology</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-728-2814</phone>
      <email>margaret.vonMehren@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

